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2School of Public Health, University of California, Berkeley, and 3Department of Medicine,
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Little is known about the clinical presentation and outcomes as-
sociated with spinal implant infections. Here, we describe a sin-
gle center’s experience in a retrospective cohort of 109
individuals with spinal implant infections, including clinical,
microbiological, therapeutic, and outcome data.
Keywords. spinal implant infection; infectious diseases
consultation; surgical site infections; vertebral osteomyelitis;
discitis.
Spinal surgeries involving implants have become increasingly
common in the United States over the past 20 years [1–3]. Spi-
nal implant infection is an important complication, arising in
2%–5% of spinal interventions and associated with significant
patient morbidity [4–6]. Insufficient guidance is available for
the management of spinal implant infections. This is largely
due to the limited data regarding the clinical presentation, nat-
ural history, microbiology, and outcomes of individuals with
this complication. Understanding the clinical manifestations
and microbiologic features of these infections may provide op-
portunities to improve the management of spinal implant infec-
tions. In this study, we describe the clinical characteristics and
outcomes of patients with spinal implant infections in a single
tertiary referral medical center.
METHODS
Study Population
This was a single-center, retrospective descriptive cohort at the
University of California San Francisco (UCSF). Individuals
were included if they had spinal surgery performed at UCSF,
had a spinal implant, and if they met the National Healthcare
Safety Network definition of surgical site infection between Jan-
uary 2009 through July 2013 [7].
Measurements and Definitions
Demographic, clinical, microbiologic, treatment, and outcome
data were collected from the electronic medical record. Individ-
uals were only included once (a second infection during the
study period was considered to be a recurrence). Since July
2010, treatment has been determined using a standardized pro-
tocol (SOP), developed to provide guidance on antibiotic selec-
tion and duration, including oral suppressive therapy. Prior to
2010, participants were managed per provider discretion. Early
and late-onset spinal implant infections were defined as those
occurring more than 30 days or 30 days or longer after the im-
plant was placed, respectively.
Outcomes
Participant vital status was determined by manual chart review,
search of public internet-based death records, search of the Na-
tional Center for Health Statistics national death index (through
2012), and search of the Social Security Administration death
master file (through 2013). Need for repeat surgery was defined
as spinal surgery performed at the affected vertebral levels dur-
ing the study period for any reason (planned or unplanned).
Recurrence of infection was defined as any infection (by any or-
ganism) at the affected vertebral levels during the study period.
All outcomes were considered through 365 days.
Statistical Analysis
Univariate analyses were performed using Fisher exact test for
categorical data and t tests for continuous data to compare var-
iables. With respect to outcomes, Cox proportional hazards
models were used, and tied survival times were addressed
using the Efron method [8]. All statistical procedures were con-
ducted using R version 3.2.2 (Vienna, Austria). The UCSF
Committee for Human Research approved this study.
RESULTS
Clinical Features
A total of 109 individuals with spinal implant infection were
identified during the study period. Full clinical data are summa-
rized in Table 1. The mean age was 56 years, 48/109 (44%) were
immunocompromised, and 58/109 (53%) had a history of prior
spinal surgery. At presentation, inflammatory markers were
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elevated with mean C-reactive protein (CRP) significantly high-
er among those with early vs late-onset infection (P < .001). The
mean white blood cell count (WBC) was in the normal range.
Ninety-six (88%) patients received inpatient infectious diseases
(ID) consultation.
Microbiology
The most common cause of monomicrobial infection was
Staphylococcus aureus, accounting for 32% of infections. Mono-
microbial infection due to gram-negative organisms was seen in
only 4 (4%) cases. Forty-six infections (42%) were polymicro-
bial, and 21 of these (46%) contained at least 1 gram-negative
organism. Fifteen (13%) individuals had positive blood cultures,
of which 53% were due to S. aureus (37% of these were methi-
cillin resistant [MRSA]). Other organisms isolated from blood
culture included Corynebacterium spp. (n = 1), Staphylococcus
epidermidis (n = 1), Escherichia coli (n = 1), Pseudomonas aeru-
ginosa (n = 1), Enterococcus spp. (n = 1), and polymicrobial
(n = 2). There were no significant differences in microbiology
between early vs late-onset infections (P = .20).
Table 1. Baseline Characteristics of Individuals With Spinal Implant
Infections
Characteristic
All Patients
(N = 109)
Age, mean years (SD) 56.1 (18.2)
Race/Ethnicity
White 92 (84.4)
Hispanic 7 (6.4)
African-American 4 (3.7)
Asian 3 (2.8)
Native American 1 (0.9)
Other 2 (1.8)
Female gender 56 (51.4)
Smoking status
Current 8 (7.3)
Former 42 (38.5)
Never 59 (54.1)
Diabetes mellitus 16 (14.7)
Chronic kidney disease 7 (6.4)
Cirrhosis 2 (1.8)
HIV/AIDS 3 (2.8)
Injection drug use 1 (0.9)
Immunological abnormalitya 48 (44.0)
Receipt of immunosuppressive medicationsb (iatrogenic
immunocompromised)
15 (13.8)
Surgical service
Orthopedics 48 (44.0)
Neurosurgery 57 (52.3)
Combined 4 (3.7)
Surgical approach
Posterior 93 (85.3)
Anterior 4 (3.7)
Combined 12 (11.0)
Depth of infection
Superficial only (dermis and above) 14 (12.8)
Subdermal (from dermis to fascia) 13 (11.9)
Deep (below fascia) 81 (74.3)
Unknown 1 (0.9)
Surgical procedure preceding infection
Primary 49 (45.0)
Revision 60 (55.1)
Infection timing
Early (<30 days post-surgery) 80 (73.4)
Late (≥30 days post-surgery) 29 (26.6)
Vertebral bodies involved, mean bodies (SD) 5.3 (4.4)
Past history of any spinal surgery 58 (53.2)
Documented back pain at presentation 49 (45.0)
Neurological deficit at presentation 9 (8.3)
Past osteomyelitis/discitis 6 (5.5)
C-reactive protein at diagnosis (perioperative),
mean mg/L (SD)
89.8 (78.8)
(n = 86)
Erythrocyte sedimentation rate at diagnosis,
mean mm/hr (SD)
57.4 (27.8)
(n = 85)
White blood cell count at diagnosis, mean cells x109 per
liter (SD)
10.1 (4.7)
Pathogen
Methicillin-resistant Staphylococcus aureus 12 (11.0)
Methicillin-susceptible Staphylococcus aureus 23 (21.1)
Staphylococcus epidermidis 9 (8.3)
Polymicrobialc 46 (42.2)
Table 1 continued.
Characteristic
All Patients
(N = 109)
Enteric gram-negative bacilli 3 (2.8)
Enterococcus 3 (2.8)
Propionibacterium acnes 2 (1.8)
Pseudomonas 1 (0.9)
Streptococcus 1 (0.9)
Culture negative at surgery 6 (5.5)
Otherd 3 (2.8)
Positive blood cultures at presentation matching spinal
isolate
15 (13.4)
Duration of intravenous therapy, mean days (SD) 33.1 (23.8)
Use of rifampin in treatment 53 (48.6)
Inpatient infectious diseases consultation 96 (88.1)
Removal of implant 13 (12.3)
Placement of new spinal implant 15 (13.8)
Outcomes
Recurrence of infection 9 (8.3)
Need for repeat surgery 22 (20.2)
One year all-cause mortality 5 (5.6)
Composite outcome (at least 1 of the 3 above) 28 (24.8)
Time to recurrence of infection, mean days (SD)e 62.9 (48.0)
Time to repeat surgery, mean days (SD)e 49.5 (55.4)
Time to mortality, mean days (SD)e 61.4 (86.4)
Time to composite outcome, mean days (SD)e 62.9 (83.8)
All values reported as N (%) unless otherwise stated.
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency
virus; SD, standard deviation.
a Defined as having HIV/AIDS, active malignancy, autoimmune disease, or
immunodeficiency.
b Defined as receiving >2 weeks of corticosteroids, biological agent, or chemotherapy.
c Any operative specimen with more than 1 organism was considered polymicrobial.
d Includes Corynebacterium spp. and Cryptococcus spp.
e Limited to those who experienced the outcome.
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Treatment and Outcomes
Tailoring of antibiotic regimens was based on an SOP. Overall,
the mean duration of intravenous antibiotics was 33.1 days. This
duration did not significantly differ by organism or SOP use.
The mean duration of oral antibiotic treatment was not calcu-
lated given that 24 individuals (22%) remained on indefinite an-
tibiotic suppression. Rifampin was used in 53 (49%) infections
in total; in most Staphylococcal infections (26/44) and polymi-
crobial infections (24/46, all of which contained at least 1 Staph-
ylococcal species); and in 1 case each of a culture-negative,
Enterococcus species and Corynebacterium species infections.
With respect to recurrence, 6/9 (67%) were due to monomicro-
bial gram-positive organisms and none were due to monomi-
crobial gram-negative organisms. In the setting of repeat
surgery, 11/22 (50%) of the individuals had monomicrobial
gram-positive organisms (7/11, or 64%, were due to methicil-
lin-sensitive S. aureus[MSSA]) and 1 (4.5%) had a monomicro-
bial gram-negative organism. Finally, 14/28 (50%) individuals
who experienced 1 of the 3 outcomes had a monomicrobial
gram-positive infection. Of these, 9/14 (64%) were due to
MSSA.
ID consultation resulted in more rifampin use (P = .002) and
longer duration of intravenous (IV) antibiotic therapy (P < .001,
mean duration of IV therapy for ID consult vs none was 36.6 vs
7.6 days, respectively). Twenty-two individuals required repeat
surgery, 9 had recurrence of infection (all also had repeat sur-
gery), 5 died, and 28 had at least 1 of these outcomes. Given the
exploratory nature of this study, several variables were consid-
ered to better understand possible determinants of outcomes in
spinal implant infections. There were no statistically significant
differences in univariate Cox regressions for recurrence of infec-
tion, need for repeat surgery, 1-year all-cause mortality, or a
composite of these outcomes by use vs no use of the SOP (haz-
ard ratio [HR] 0, P = 1; HR 1.32, P = .56; HR 0 P = 1; HR 0.96,
P = .92, respectively), for early vs late-onset infections (HR 2.18,
P = .25; HR 1.04, P = .93; HR 1.87, P = .50; HR 1.12, P = .79, re-
spectively), rifampin use (HR 0.52, P = .36; HR 0.88, P = .76; HR
0.26, P = .23; HR 0.79, P = .53, respectively), infection depth
(HR 0.94, P = .89; HR 1.48, P = .28; HR 4.33, P = .24; HR 1.72,
P = .12, respectively), antibiotic suppression (HR 0.88, P = .87;
HR 0.51, P = .28; HR 2.20, P = .39; HR 0.70, P = .48, respective-
ly), or implant removal (HR 4.32, P = .05; HR 1.73, P = .99; HR
1.90, P = .57; HR 1.69, P = .29, respectively).
DISCUSSION
Indications for spinal surgeries are increasing as technology ad-
vances and the population ages. An understanding of the clin-
ical characteristics of spinal implant infections and their
relationship to outcomes is important to inform the develop-
ment of infection prevention and diagnostic and management
strategies. In this large retrospective cohort of patients with spi-
nal implant infections, we identified several important features.
These patients are medically complex; half of them were immu-
nocompromised and more than half had a history of prior spi-
nal surgery. While Staphylococcal species were the
predominant organisms in monomicrobial infections, in con-
trast to prior studies, most patients had polymicrobial infections
[4, 5, 9, 10]. This finding may be attributable to the volume of
lumbosacral surgical interventions performed at this institution
[11]. Spinal implant infections are associated with significant
morbidity, with 25% of our patients experiencing at least 1 of
the following: recurrent infection, need for repeat surgery, or
death. Infection timing, rifampin use, infection depth, indefinite
antibiotic suppression, and removal of implant did not influ-
ence these outcomes. A notable exception to this is the in-
creased risk of recurrence associated with implant removal,
but this likely temporally reflects removal of the hardware due
to recurrence as opposed to recurrence due to failure to remove
the hardware.
This study also highlights some of the challenges associated
with diagnosis and management of spinal implant infection.
Less than half of the patients presented with back pain, a minor-
ity had positive blood cultures, and most presented with a nor-
mal WBC count. Although the CRP was elevated on average,
there was significant variability likely reflecting heterogeneity
of both the patient population and the test itself. The erythro-
cyte sedimentation rate was less variable at the time of diagnosis
but lacks specificity. Our findings are consistent with previously
published data that raise concerns over the usefulness of inflam-
matory markers in diagnosing spinal implant infections given
poor specificity [5, 12]. Implant removal and exchange was un-
common, necessitating prolonged courses of antibiotic therapy,
and about 20% of patients were maintained on indefinite sup-
pressive antibiotics.
A major strength of this study is the size of the cohort. In the
setting of such a rare complication, this study adds to the pub-
lished experience in the clinical presentation and management
of such infections. The study included several different out-
comes of clinical interest among highly medically complex pa-
tients who are increasingly undergoing advanced medical
procedures. Finally, great care was taken to determine the out-
comes for each participant, particularly with respect to the all-
cause mortality.
There are also notable limitations. This study was performed
in a single center that serves as a tertiary referral site for complex
spinal cases, often for individuals with a prior history of surgery.
Thus, these findings may not be universally generalizable.
Among those who died, the issue of competing risks (eg, the in-
ability to develop treatment failure or need for repeat surgery) is
an important limitation. However, the number of patients who
died was low (5/109) as were the proportions for the other out-
comes. In order to address this to some degree, the composite re-
sult was used to capture more outcomes of interest. Complete
individual-level antibiotic treatment data were not available.
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In summary, despite limitations, this is a large study that
contributes to the existing literature on the clinical presenta-
tion and outcomes of individuals presenting with spinal im-
plant infection. These data support the need to establish
multicenter interdisciplinary prospective collaborations to
further investigate outcomes, risk factors, and strategies for
prevention, diagnosis, and management of spinal implant
infections.
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